clinical trial · NCT04783428
Tumor-induced Osteomalacia Disease Monitoring Program
Tumor-induced Osteomalacia (TIO)No intervention
brief summary
The objectives of this observational study are to assess the long-term safety and long-term effectiveness of burosumab in patients with TIO who are being treated with burosumab as prescribed by their physician and to monitor the course of the underlying phosphaturic mesenchymal tumor (PMT) overtime in patients with TIO irrespective of their treatment status.
started
Jan 31, 2022
primary completion
Feb 28, 2032
completion
Feb 28, 2032
last updated
Jun 3, 2026
detailed description
Enrolled patients may or may not be treated with commercially available burosumab during the TIO DMP at the discretion of their treating physician. Given the observational nature of the TIO DMP, specific treatments or supportive management will not be provided as part of the study.
official title
Tumor-induced Osteomalacia Disease Monitoring Program (TIO DMP)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol